PFS
ZYNE

Prospera Financial Services’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Prospera Financial Services’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-400
Closed -$1K – 2736
2022
Q1 		$1K Buy
+400
New +$951 ﹤0.01% 2710

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return

Prospera Financial Services's ZYNE Position: Q2 2022 in Review

Prospera Financial Services sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2022, closing a stake of 400 shares — an estimated $1K sold.

Prospera Financial Services first reported a position in ZYNE in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 56 funds tracked by Wall St. Rank hold ZYNE as of Q2 2022.

  • Prospera Financial Services reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2022 after selling out during the quarter.
  • Prospera Financial Services sold 400 Zynerba Pharmaceuticals, Inc shares in Q2 2022, an estimated $1K.
  • Prospera Financial Services first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2022 and held it in 1 quarter.
  • Prospera Financial Services's Zynerba Pharmaceuticals, Inc position peaked at $1K in Q1 2022.
  • 56 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2022.

Based on Prospera Financial Services's 13F filing for Q2 2022, filed 8 Aug 2022.